Publications
345
Citations
17,003
Est. group size
~21
Recurring co-author estimate
Active years
30
Publishing since 1997
Andrew D. Mesecar's research focuses on understanding the structure and function of enzymes involved in disease, with a major emphasis on designing small-molecule inhibitors against SARS-CoV-2 proteins (such as the main protease Mpro and papain-like protease PLpro) as potential antiviral drugs. His group also studies enzymes relevant to cancer, antifungal therapy, and metabolic signaling, often using techniques like X-ray crystallography, cryo-EM, and biochemical assay development to guide drug design.
Publication output rose substantially from 2017 through a peak in 2023, likely driven by COVID-19-related antiviral research, but has slowed notably in 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Ugi multicomponent reactions of optically active aldehydes and chiral aminoindanols: diastereoselective synthesis of bisamides relevant to SARS-CoV-2 Mpro inhibitors
Organic & Biomolecular Chemistry · 2026
- Design, synthesis, and X-ray structural studies of potent SARS-CoV-2 Mpro inhibitors containing tetrahydroisoquinoline-3-carboxamides as P2 ligands
RSC Medicinal Chemistry · 2026
- Abstract 2714 Biochemical and Cryo-EM Structural Studies of GTP Cyclohydrolase I from Candida auris: A Potential New Target for Antifungal Therapy
Journal of Biological Chemistry · 2025
- X-ray structure of SARS-CoV-2 main protease V186G covalently bound to inhibitor Nirmatrelvir at 1.81 A
2025
- Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors
European Journal of Medicinal Chemistry · 2024
- A novel micellular fluorogenic substrate for quantitating the activity of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma (PLCγ) enzymes
PLoS ONE · 2024
- Author Correction: Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Nature · 2024
- SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads
Bioorganic & Medicinal Chemistry Letters · 2023
- Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
Communications Biology · 2023
- A novel fluorogenic reporter substrate for 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCγ2): Application to high-throughput screening for activators to treat Alzheimer's disease
SLAS DISCOVERY · 2023
- Development of a sensitive microplate assay for characterizing RNA methyltransferase activity: Implications for epitranscriptomics and drug development
Journal of Biological Chemistry · 2023
- Supplemental Materials and Methods from Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer
2023
- Supplemental Figures 1-7 and Supplemental Table 1 from Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer
2023
- Supplemental Figures 1-7 and Supplemental Table 1 from Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer
2023
- Supplemental Materials and Methods from Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer
2023
- Zenodo (CERN European Organization for Nuclear Research)×23
- Alzheimer s & Dementia×9
- bioRxiv (Cold Spring Harbor Laboratory)×8
- The FASEB Journal×7
- ChemMedChem×5
- Yuan Pu
Medicine · The Ohio State University
- Shan‐Lu Liu
Medicine · The Ohio State University
- Jingyou Yu
Medicine · The Ohio State University
- Elizabeth Sims
Medicine · Indiana University
- Amanda M. Williams
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile